South Korea Central Lab Market Insight
Published: 27 June 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
Due to rising R&D expenditures and growing demand for clinical trial services, the South Korean central lab market is anticipated to grow at a robust CAGR of 12.1%.
South Korea Central Lab Market Insights Forecasts to 2035
- The South Korea Central Lab Market Size Was Estimated USD 133.29 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 12.1% from 2025 to 2035
- The South Korea Central Lab Market Size is Expected to rise around USD 417.77 Million by 2035
Notable Insights for the South Korea Central Lab Market
- Based on service segmentation, Genetic Services is expected to increase at the highest rate, while Biomarker Services had the biggest revenue share in 2024.
- Pharmaceutical and biotechnology businesses have the largest market share (61.17%) according to end-user segmentation, and CROs are a rapidly expanding end-user group.
- While increasing clinical research, trial numbers, and biopharmaceutical investments continue to propel the expansion of the central laboratory market, South Korea maintains strict regulations for laboratory quality and clinical sample labeling.
- Growing clinical research activity boosts South Korea's central laboratory sector, where pharmaceutical and biotechnology firms own more than 61% of the market, encouraging continued investment and industry growth.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- Central Lab Market Intelligence & Clinical Trial Analytics
Insights from Decisions Advisors are offered in great detail in regard to the central laboratory market in South Korea with regards to biomarker and genetic testing. Growth opportunities have been highlighted within various industries including pharmaceuticals and biotechnology.
- Robust Research Methodology with Accurate Forecasting Models
This study is an amalgamation of primary research of interviews with the key players in the central labs, pharma, and CRO space, along with secondary research using clinical trial database, regulatory journals, and industry reports.
- Comprehensive Competitive and Ecosystem Analysis
Some top lab services and tech firms get reviewed inside this report. Details unfold around partnerships that shape moves ahead, how each stands against rivals, what rules they follow, plus chances to nudge markets into fresh forms. The look stays sharp throughout.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Central Lab Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Central Lab Market
- LabCorp (Covance)
- IQVIA
- Eurofins Scientific
- ICON plc
- LabConnect
- Medpace
- Cerba Research
- Syneos Health
- Charles River Laboratories
- ·Thermo Fisher Scientific
Recent Developments:
- In March 2025, Labcorp rolled out a more refined system for connecting lab workflows worldwide - aimed at smoothing how clinical samples are handled across drug studies.
- In June 2024, fresh lab service deals had expanded Eurofins Scientific’s reach in clinical testing across Asia-Pacific, boosting central lab capabilities just as biopharma trials began needing more outsourced support.
Market Segmentation:
South Korea Central Lab Market, By Service Type
- Biomarker Services
- Genetic Services
- Microbiology Services
- Anatomic Pathology/Histology
- Specimen Management & Storage
- Special Chemistry Services
South Korea Central Lab Market, By End-User
-
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
South Korea Central Lab Market, By Clinical Trial Phase
-
- Phase I
- Phase II
- Phase III
- Phase IV
Expert Views:
There is expected to be significant growth in the South Korea central lab market due to the increase in clinical trials, increased investment in research and development, and increased need for biomarker and genetic tests. The participation of pharmaceutical companies and contract research organizations ensures the scalability of the market. The regulatory environment, along with advanced diagnostic technologies, contributes towards the growth of the market.
Author: Govind and Krishna By Decisions Advisors and Consulting